Skip to main content
  • Home
  • Heart Failure Management in a Changing Paradigm

Heart Failure Management in a Changing Paradigm

Topic:
  • Heart Failure

Available Credit:

  • 1 EBAC

Course Published On:

Course Expiry Date:

Title

Overview

During this unique broadcast, Radcliffe Medical Education brings together a globally-renowned European and American faculty to participate in a roundtable discussion. Radcliffe’s roundtable discussions are to provide both a reflection on the HF landscape following published data at congress and to examine what future developments can be expected at forthcoming events via lively discussion and data presentations.

Prof Andrew Coats (University of Warwick, UK) leads proceedings, and is joined by Dr Shelley Zieroth (University of Manitoba, CA), Dr Javed Butler (University of Mississippi Medical Center, Jackson, MS) and Dr Piotr Ponikowski (Wroclaw Medical University, Wroclaw, PL) for an insightful presentation and a discussion. 

Disclosure

In compliance with EBAC guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. 

The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities. This programme is supported by an unrestricted educational grant from Medtronic. 

Terms & Conditions

Radcliffe Education requires contributors to our CME programmes to disclose any relevant financial relationships that have occurred within the past 12 months that could create a conflict of interest. These will be identified in the faculty section if applicable.

 

The session, ‘Heart Failure Management in a Changing Paradigm’ is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credits. 

 

Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).

 

Through an agreement between the European Board for Accreditation in Cardiology and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website.

Support Statement

This programme is supported by an educational grant from the Boehringer Ingelheim ​and Lilly Alliance.

INSTRUCTIONS TO PARTICIPANTS

There is no fee for taking part in this online learning activity.

 

Activities are designed to be completed within 60 minutes and must be completed by the registered user. Physicians should only claim credits for time spent on the activity. To successfully earn credit, participants must complete the activity in full in the indicated time frame.

 

To complete the course and claim certification participants must:

 

  • Read the course outline information supplied and complete pre-test questions if supplied prior to starting the activity. Users must read and study the activity in its entirety before completing the post-test questions.

 

  • Your results will be automatically saved and if a pass score is achieved (where applicable), you may be eligible to claim credit for the activity and receive a certificate of completion.

Target Audience

This programme is intended to educate:

  • Global Heart Failure Physicians
  • General Cardiologists

Learning Objectives

Upon participation in the roundtable discussion physicians will be able to:

  • Recall the utility of EF in heart failure treatment, patient selection and treatment response
  • Identify alternative measures to EF for the purposes HF severity and therapeutic efficacy
  • InIncorporate quality of life measures for assessing therapeutic efficacy in HF
  • Recall outcomes from heart failure trials from recent congress and publications and their impact on practice
Register now Log in

Module

Title

Duration

Speakers

Session 1 EF in context (10 mins) Shelley Zieroth ()
Session 2 Life beyond EF (10 mins) Javed Butler ()
Session 3 Round-up of New Data in HF and How to Apply Them to Practice Piotr Ponikowski ()
Session 4 Discussion Andrew Coats ()
Session 1.

EF in context (10 mins)

Duration:

Speakers: Shelley Zieroth ()

Session 2.

Life beyond EF (10 mins)

Duration:

Speakers: Javed Butler ()

Session 3.

Round-up of New Data in HF and How to Apply Them to Practice

Duration:

Speakers: Piotr Ponikowski ()

Session 4.

Discussion

Duration:

Speakers: Andrew Coats ()

Speaker

Shelley Zieroth

Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada

Dr Shelley Zieroth is currently at SBH Heart Failure and Transplant Clinics and serves as Head of the Medical Heart Failure Program, WRHA Cardiac Sciences Program, and as Associate Professor of the Section of Cardiology at the University of Manitoba, Canada.

View full profile

Javed Butler

University of Mississippi Medical Center, Jackson, MS, US

Javed Butler, MD, MPH, MBA, is the Patrick H Lehan Chair in Cardiovascular Research, and Professor and Chairman of the Department of Medicine at the University of Mississippi Medical Center in Jackson, Mississippi. He is also Professor of Physiology.

View full profile

Piotr Ponikowski

Wroclaw Medical University, Wroclaw, Poland

Piotr Ponikowski is Head of the Department of Heart Diseases, Wroclaw Medical University and Head of the Cardiology Department at the Center for Heart Diseases at 4th Military Hospital, Wroclaw, Poland.

View full profile

Chair

Andrew Coats

Monash University, Australia and University of Warwick, UK

Prof Coats is Joint Academic Vice-President of Monash University, Australia and the University of Warwick, UK. His research greatly influenced the treatment for chronic heart failure, promoting exercise training instead of bed rest. He has a vast experience in education and publishing.

View full profile

1.00 European Board for Accreditation in Cardiology (EBAC)

Related Courses

Hypertrophic Cardiomyopathy in Review: ESC–HFA 2022 & How to Differentiate HCM From Its Phenocopies
  • 0.50 AMA PRA Credit

Learning objectives

  • Recall the efficacy and safety of existing HCM treatments and summarise results from ongoing trials with experimental treatments
  • Differentiate the signs and symptoms of HCM from other conditions that frequently mask, or mimic the disease and in the presence of comorbidities
See more
Making Gains in HFpEF: An Appraisal of Where We Are Now

Learning objectives

  • Identify HFpEF patients who may benefit from being initiated on an SGLT-2 inhibitor
  • Recall current inertia rates amongst prescribers who manage heart failure
  • Adopt effective treatment strategies for HFpEF patients early in the disease course
  • Recall current guideline directed medical therapy options in HFpEF
  • Review clinical, real world and quality of life evidence for the use of SGLT-2 inhibitors in HFpEF
See more
Hypertrophic Cardiomyopathy in Review: Highlights of ACC 2022
  • 0.25 AMA PRA Credit

Learning objectives

  • Recall the efficacy and safety of existing HCM treatments and summarise results from ongoing trials with experimental treatments
See more
The 2022 ACC Heart Failure Guidelines: What Do They Mean for Your Practice?

Learning objectives

  • Summarise the main updates to the 2022 ACC heart failure (HF) guidelines
  • Compare updates from the ACC with the 2021 ESC HF guidelines
  • Recall guideline recommendations for the initiation of foundational therapy for heart failure
  • Adopt foundational GMDT early in the disease course
  • Postulate how ejection fraction will be used in future trials and in future guidelines
  • Review existing and forthcoming trial evidence on SGLT-2 inhibitors in HFpEF
See more
Hypertrophic Cardiomyopathy: Application of Emerging Data and Genetic Testing in Clinical Practice
  • 0.75 AMA PRA Credit

Learning objectives

  • Recall the efficacy and safety of existing HCM treatments
  • Summarise results from ongoing trials with experimental treatments
  • Stratify individuals with HCM signs and symptoms for subsequent investigation and/or genetic screening
See more
Hypertrophic Cardiomyopathy in Review: Highlights from HFA 2021
  • 0.50 AMA PRA Credit

Learning objectives

  • Identify patients likely to benefit from invasive procedures versus pharmacological treatment
  • Stratify individuals with HCM signs and symptoms for subsequent investigation and/or genetic screening
See more
Hypertrophic Cardiomyopathy in Review: Highlights 2019-2021
  • 0.25 AMA PRA Credit

Learning objectives

  • Recall the efficacy and safety of existing HCM treatments
  • Summarize results from ongoing trials with experimental treatments
See more
Malaysia In Focus - ARNI Data And Its Implications On Clinical Practice
  • 1.00 MMA

Learning objectives

  • Understand the latest ARNI data in HFpEF and HFrEF
  • Understand how emerging data relates to current practice in Malaysia
  • Apply current understanding of ARNI therapy in appropriate heart failure patients
See more
Malaysia In Focus - Reverse Cardiac Remodelling Educational Programme
  • 1.00 MMA

Learning objectives

  • Define cardiac remodelling, with particular focus on the influence of cardiovascular damage, pathogenic risk factors and the structural and functional changes in the left ventricle.
  • List the main clinical implications of cardiac remodelling.
  • Summarise the relationship between circulating biomarkers, such as NT-proBNP, troponin and sST2, with the extent left ventricular remodelling in subjects with HF.
  • Interpret the most recent clinical data from pharmacological and device-based studies in HFrEF and HfpEF.
  • Recall the evidence for reverse cardiac remodelling brought about through ARNi therapy, including (but not limited to) PROVE-HF and EVALUATE-HF.
  • Review real-world insight into the impact that ARNi therapy has on cardiac reverse remodelling.
See more
Sodium–Glucose Co-transporter 2 Inhibitors in Heart Failure
  • 1.00 EBAC

Learning objectives

  • Understand the SGLT2 inhibitor cardiovascular outcome trial (CVOT) data.
  • Differentiate the latest guideline updates for the treatment of T2D and their recommendations regarding the importance of considering comorbidities, including atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF).
  • Apply clinical and real-world evidence of the SGLT2 inhibitor class for use in prevention of hospitalisation in HF, as well as future ongoing studies in the treatment of HF.
  • Assess the interrelationships linking diabetes, HF and CVD.
  • Interpret the potential cardio-renal mechanisms of the SGLT2 inhibitor class in reducing the risk of CV, including HF.
  • Evaluate emerging data of the treatment of HF with SGLT2 inhibitors in patients with or without T2DM.
See more